Monogram Technologies (Monogram Technologies) ROE % Adjusted to Book Value : -15.73% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Monogram Technologies ROE % Adjusted to Book Value?

Monogram Technologies's ROE % for the quarter that ended in Mar. 2024 was -118.76%. Monogram Technologies's PB Ratio for the quarter that ended in Mar. 2024 was 7.55. Monogram Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -15.73%.

Monogram Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Monogram Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monogram Technologies ROE % Adjusted to Book Value Chart

Monogram Technologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-19.44

Monogram Technologies Quarterly Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial												-	-33.77	-5.16	-14.35	-15.73

Competitive Comparison of Monogram Technologies's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Monogram Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monogram Technologies's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Monogram Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Monogram Technologies's ROE % Adjusted to Book Value falls into.

Monogram Technologies ROE % Adjusted to Book Value Calculation

Monogram Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-156.67%	/	8.06
	=	-19.44%

Monogram Technologies's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-118.76%	/	7.55
	=	-15.73%

Monogram Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Monogram Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Monogram Technologies (Monogram Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monogram Technologies Inc (NAS:MGRM) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

J7J:Germany

Address

3913 Todd Lane, Suite 307, Austin, TX, USA, 78744

Website

https://www.monogramorthopedics.com

Monogram Orthopaedics Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.

Executives

Paul H Riss	director
Noel Knape	officer: Chief Financial Officer	3913 TODD LANE, AUSTIN TX 78744
Benjamin Sexson	director, 10 percent owner, officer: Chief Executive Officer	3913 TODD LANE, AUSTIN TX 78744
Noel Goddard	director	3913 TODD LANE, AUSTIN TX 78744
Kamran Shamaei	officer: Chief Technology Officer	3913 TODD LANE, AUSTIN TX 78744
Douglas Unis	director	3913 TODD LANE, AUSTIN TX 78744